RT Book, Section
A1 Rowley, Freda M.
A2 Olson, Kent R.
A2 Anderson, Ilene B.
A2 Benowitz, Neal L.
A2 Blanc, Paul D.
A2 Clark, Richard F.
A2 Kearney, Thomas E.
A2 Kim-Katz, Susan Y.
A2 Wu, Alan H. B.
SR Print(0)
ID 1179990524
T1 ANTICONVULSANTS, NEWER
T2 Poisoning & Drug Overdose, 7e
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9780071839792
LK accessmedicine.mhmedical.com/content.aspx?aid=1179990524
RD 2022/05/20
AB Developed  for  the  treatment  of  partial  and  generalized  seizure  disorders,  these  second-  and  third-generation  anticonvulsants  are  finding  wider  use  in  the  treatment  of  chronic  and  neuropathic  pain  syndromes;  mood  disorders,  including  bipolar  and  generalized  anxiety  disorders;  and  migraine  headache  prophylaxis.  Serious  adverse  effects  with  the  therapeutic  use  of  ezogabine  (retinal  pigment  abnormalities,  blue  skin  discoloration),  felbamate  (aplastic  anemia,  hepatic  failure)  and  vigabatrin  (permanent  visual  field  deficits)  have  led  to  restrictions  in  their  use.